News & Events

CatSci commissions new material science lab as part of ambition to integrate medicines development

CatSci commissions new material science lab as part of ambition to integrate medicines development

Cardiff, UK – 27 April 2021 – CatSci Ltd, a scientifically-led, commercially-minded and award-winning innovation partner for medicines development, has commissioned a new material science laboratory to expand its integrated drug development capabilities. The new lab will be operational from 1st June 2021, offering solid state expertise for both emerging and established pharma companies. This is part of CatSci’s £3 million investment plan and is another important milestone of the Company's journey to become the leading innovation partner for pharmaceutical development

In many cases, the qualities sought in a drug substance are not well-suited to the drug product. Through fully integrated thinking, with an excellent line of sight of the objectives and challenges of medicines development, CatSci aims to offer scientifically-led, data-backed solutions. The new lab bolsters CatSci’s material science offering, adding strategic value to the journey from molecule to medicine for all customers.

Dr Ross Burn, CEO, said: “Expanding our material science capabilities will enable us to provide a fully sustainable, integrated solution that will ultimately de-risk our customers’ pharmaceutical pipeline.

“Our agile, end-in-mind approach adds true value to both our core customer segments: it helps maximise the chance of small molecule success for emerging pharma companies and, by taking a data-rich approach earlier in the process, we can minimise risks in the latter stages of drug development for large pharma companies.”

Dr Robert Dennehy, Director of Crystallisation and Solid State, said: “By linking an API’s physical properties and pre-formulation development, CatSci aims to break down the silos between drug substance and drug product, expediting medicines development. In addition, the crystallisation development step in small molecule drug development can be one of the most environmentally damaging and less well understood. Opening this lab expands our ability to design and develop scalable and robust crystallisations for our customers, improving the economic and environmental sustainability of their pharmaceutical manufacturing processes.

“Our experience and expertise across the CMC landscape mean that we fully understand our customers’ project challenges and deliver tailored solutions right first time, every time.”

To celebrate, CatSci will be holding a virtual material science symposium on ‘Material Science in Drug Development: A Holistic Approach’ on 3rd June 2021, for which further announcements will be made in due course.

About CatSci

CatSci Ltd is an award-winning innovation partner for medicines development, dedicated to developing economically and environmentally sustainable pharmaceutical manufacturing processes. We proudly serve customers across the globe, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies including catalysis, material science and analytical development.

Agile, commercially-minded and scientifically-led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class small molecule therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world.

CatSci works efficiently with your preferred partners, while continually strengthening our own industry-leading partnerships across the pharmaceutical supply chain, to address your dynamic drug substance development needs. A true extension of your team, we are a dependable, trusted partner for innovation that takes the time to understand your project objectives and provide you with perfect-for-purpose solutions.

Recognition includes wins at the prestigious CPhI Pharma Awards (Excellence in Pharma: Contract Services and Outsourcing), at the highly esteemed Cardiff Business Awards (International Business of the Year) and the Wales STEM 2020 Awards (STEM scale-up of the year). We were also recently shortlisted for the International Expansion Entrepreneur of the Year at the Barclays Entrepreneur Awards 2020 and the 2020 Bionow Export Award.

Find out more at, or connect with us via Twitter and LinkedIn.

For more information please contact:

back to news


Tim WatsonPartner